172 related articles for article (PubMed ID: 25695549)
1. Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy.
Mahdi H; Rizzo A; Rose PG
Int J Gynecol Cancer; 2015 Mar; 25(3):467-73. PubMed ID: 25695549
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
Dietrich CS; Modesitt SC; DePriest PD; Ueland FR; Wilder J; Reedy MB; Pavlik EJ; Kryscio R; Cibull M; Giesler J; Manahan K; Huh W; Cohn D; Powell M; Slomovitz B; Higgins RV; Merritt W; Hunter J; Puls L; Gehrig P; van Nagell JR
Gynecol Oncol; 2005 Dec; 99(3):557-63. PubMed ID: 16154185
[TBL] [Abstract][Full Text] [Related]
3. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
Gynecol Oncol; 1999 Aug; 74(2):272-7. PubMed ID: 10419744
[TBL] [Abstract][Full Text] [Related]
4. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
5. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
[TBL] [Abstract][Full Text] [Related]
6. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
Fader AN; Nagel C; Axtell AE; Zanotti KM; Kelley JL; Moore KN; Secord AA; Walsh CS; Huh WK; Gehrig PA; Gibbons H; Rose PG; Havrilesky LJ; Tuller E; Drake RD; Bottsford-Miller J; O'Malley DM;
Gynecol Oncol; 2009 Mar; 112(3):558-62. PubMed ID: 19118888
[TBL] [Abstract][Full Text] [Related]
7. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Dalton HJ; Fleming ND; Sun CC; Bhosale P; Schmeler KM; Gershenson DM
Gynecol Oncol; 2017 Apr; 145(1):37-40. PubMed ID: 28139261
[TBL] [Abstract][Full Text] [Related]
8. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
[TBL] [Abstract][Full Text] [Related]
9. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.
Shechter-Maor G; Bruchim I; Ben-Harim Z; Altaras M; Fishman A
Int J Gynecol Cancer; 2009 May; 19(4):662-4. PubMed ID: 19509567
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Eng KH; Hanlon BM; Bradley WH; Szender JB
Gynecol Oncol; 2015 Nov; 139(2):228-35. PubMed ID: 26383827
[TBL] [Abstract][Full Text] [Related]
11. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
[TBL] [Abstract][Full Text] [Related]
12. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.
Desai NB; Kiess AP; Kollmeier MA; Abu-Rustum NR; Makker V; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Dec; 131(3):604-8. PubMed ID: 24055615
[TBL] [Abstract][Full Text] [Related]
13. The importance of chemotherapy and radiation in uterine papillary serous carcinoma.
Viswanathan AN; Macklin EA; Berkowitz R; Matulonis U
Gynecol Oncol; 2011 Dec; 123(3):542-7. PubMed ID: 21963091
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma.
Low JS; Wong EH; Tan HS; Yap SP; Chua EJ; Sethi VK; Soh LT; Low J; Tay EH; Chew SH
Gynecol Oncol; 2005 Apr; 97(1):171-7. PubMed ID: 15790454
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Li Y; Yang Y; Shang YM; Zheng H
Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
[TBL] [Abstract][Full Text] [Related]
17. Role of adjuvant chemotherapy in patients with early stage uterine papillary serous cancer.
Mahdavi A; Tajalli TR; Dalmar A; Vasilev SA; Lentz SE; Berman ML
Int J Gynecol Cancer; 2011 Nov; 21(8):1436-40. PubMed ID: 21997174
[TBL] [Abstract][Full Text] [Related]
18. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel.
Vaidya AP; Littell R; Krasner C; Duska LR
Int J Gynecol Cancer; 2006; 16 Suppl 1():267-72. PubMed ID: 16515602
[TBL] [Abstract][Full Text] [Related]
19. Management of platinum-sensitive recurrent ovarian cancer.
Pfisterer J; Ledermann JA
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
[TBL] [Abstract][Full Text] [Related]
20. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.
Fader AN; Drake RD; O'Malley DM; Gibbons HE; Huh WK; Havrilesky LJ; Gehrig PA; Tuller E; Axtell AE; Zanotti KM;
Cancer; 2009 May; 115(10):2119-27. PubMed ID: 19306417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
